J
James L. Riley
Researcher at University of Pennsylvania
Publications - 170
Citations - 24311
James L. Riley is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: T cell & Cytotoxic T cell. The author has an hindex of 71, co-authored 159 publications receiving 21496 citations. Previous affiliations of James L. Riley include Walter Reed Army Institute of Research & Children's Hospital of Philadelphia.
Papers
More filters
Journal ArticleDOI
CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms
Richard V. Parry,Jens M. Chemnitz,Kenneth A. Frauwirth,Anthony R. Lanfranco,Inbal Braunstein,Sumire V. Kobayashi,Peter S. Linsley,Craig B. Thompson,James L. Riley +8 more
TL;DR: In this paper, CTLA-4 and PD-1 signaling inhibited Akt phosphorylation by preventing CD3/CD28-mediated upregulation of glucose metabolism and Akt activity, but each accomplished this regulation using separate mechanisms.
Journal ArticleDOI
The CD28 signaling pathway regulates glucose metabolism.
Kenneth A. Frauwirth,James L. Riley,Marian H. Harris,Richard V. Parry,Jeffrey C. Rathmell,David R. Plas,Rebecca Elstrom,Carl H. June,Craig B. Thompson +8 more
TL;DR: It is shown that CD28 costimulation functions to increase glycolytic flux, allowing T cells to anticipate energetic and biosynthetic needs associated with a sustained response.
Journal ArticleDOI
Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases
Elena E. Perez,Jianbin Wang,Jeffrey C. Miller,Yann Jouvenot,Yann Jouvenot,Kenneth Kim,Olga Liu,Nathaniel Wang,Gary Lee,Victor Bartsevich,Ya Li Lee,Dmitry Guschin,Igor Rupniewski,Adam James Waite,Carmine Carpenito,Richard G. Carroll,Jordan S. Orange,Fyodor D. Urnov,Edward J. Rebar,Dale Ando,Philip D. Gregory,James L. Riley,Michael C. Holmes,Carl H. June +23 more
TL;DR: O adoptive transfer of ex vivo expanded CCR5 ZFN–modified autologous CD4+ T cells in HIV patients is an attractive approach for the treatment of HIV-1 infection.
Journal ArticleDOI
Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo
Michael C. Milone,Jonathan D. Fish,Jonathan D. Fish,Carmine Carpenito,Richard G. Carroll,Gwendolyn K. Binder,David T. Teachey,David T. Teachey,Minu Samanta,Mehdi Lakhal,Brian S. Gloss,Gwenn Danet-Desnoyers,Dario Campana,James L. Riley,Stephan A. Grupp,Stephan A. Grupp,Carl H. June +16 more
TL;DR: It is suggested that incorporation of the CD137 signaling domain in CARs should improve the persistence of CARs in the hematologic malignancies and hence maximize their antitumor activity.
Journal ArticleDOI
SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation.
TL;DR: It is suggested that colocalization of PD-1 with CD3 and/or CD28 may be necessary for inhibition of T cell activation, and that recruitment of Src homology region 2 domain-containing phosphatase-1 (SHP-1) and SHP-2, and not the adaptor SRC homology 2 domain -containing molecule 1A, to the ITSM domain is needed.